PepGen Net Income Growth & History (PEPG)
PepGen's net income was −$89.7M for fiscal 2025.
View full PepGen company overviewPepGen annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$89.7M | $326,000 | — |
| 2024 | 2024-12-31 | −$90.0M | −$11.4M | — |
| 2023 | 2023-12-31 | −$78.6M | −$9.5M | — |
| 2022 | 2022-12-31 | −$69.1M | −$41.8M | — |
| 2021 | 2021-12-31 | −$27.3M | — | — |
PepGen quarterly net income
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$17.8M | $5.3M | — |
| Q1 2026 | 2026-03-31 | −$17.8M | $12.4M | — |
| Q4 2025 | 2025-12-31 | −$18.3M | $3.9M | — |
| Q3 2025 | 2025-09-30 | −$18.0M | $3.4M | — |
| Q2 2025 | 2025-06-30 | −$23.1M | $5.2M | — |
| Q1 2025 | 2025-03-31 | −$30.2M | −$12.2M | — |
| Q4 2024 | 2024-12-31 | −$22.2M | −$2.7M | — |
| Q3 2024 | 2024-09-30 | −$21.4M | $1.9M | — |
| Q2 2024 | 2024-06-30 | −$28.3M | −$8.8M | — |
| Q1 2024 | 2024-03-31 | −$18.0M | −$1.7M | — |
| Q4 2023 | 2023-12-31 | −$19.5M | −$4.6M | — |
| Q3 2023 | 2023-09-30 | −$23.3M | −$4.7M | — |
| Q2 2023 | 2023-06-30 | −$19.5M | −$2.2M | — |
| Q1 2023 | 2023-03-31 | −$16.3M | $1.9M | — |
| Q4 2022 | 2022-12-31 | −$14.9M | −$7.8M | — |
| Q3 2022 | 2022-09-30 | −$18.6M | −$10.5M | — |
| Q2 2022 | 2022-06-30 | −$17.3M | −$11.9M | — |
| Q1 2022 | 2022-03-31 | −$18.2M | −$11.6M | — |
| Q4 2021 | 2021-12-31 | −$7.1M | — | — |
| Q3 2021 | 2021-09-30 | −$8.1M | — | — |
| Q2 2021 | 2021-06-30 | −$5.4M | — | — |
| Q1 2021 | 2021-03-31 | −$6.6M | — | — |
PepGen net income trends
Between the periods ended 2021-12-31 and 2025-12-31, PepGen's net income decreased from −$27.3M to −$89.7M, a change of −$62.4M. The latest reported quarter, Q2 2026, shows −$17.8M.
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PepGen source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...